Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04411472




Registration number
NCT04411472
Ethics application status
Date submitted
28/05/2020
Date registered
2/06/2020
Date last updated
3/06/2024

Titles & IDs
Public title
(Revival) Study to Investigate the Efficacy and Safety of Alkaline Phosphatase in Patients With Sepsis-Associated AKI
Scientific title
A DB, Placebo-Controlled, Two-Arm Parallel-Group, Phase 3 RCT to Investigate the Efficacy and Safety of Recombinant Human Alkaline Phosphatase for Treatment of Patients With SA-AKI
Secondary ID [1] 0 0
AP-recAP-AKI-03-01
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Acute Kidney Injury Due to Sepsis 0 0
Condition category
Condition code
Infection 0 0 0 0
Studies of infection and infectious agents
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders
Renal and Urogenital 0 0 0 0
Kidney disease
Injuries and Accidents 0 0 0 0
Other injuries and accidents

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Other - Recombinant human alkaline phosphatase
Other interventions - Placebo

Experimental: active - recombinant human alkaline phosphatase 1.6mg/kg 3 daily 1 hour infusions

Placebo comparator: placebo - matching placebo


Treatment: Other: Recombinant human alkaline phosphatase
patients with SA-AKI are randomly assigned in a 1:1 ratio to either placebo or 1.6 mg/kg recAP.

Other interventions: Placebo
Placebo
Intervention code [1] 0 0
Treatment: Other
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
28-day All-cause Mortality: Main Trial Population
Timepoint [1] 0 0
28 days
Primary outcome [2] 0 0
28-day All-cause Mortality: Moderate Chronic Kidney Disease Population
Timepoint [2] 0 0
28 days
Primary outcome [3] 0 0
28-day All-cause Mortality: COVID-19 Population
Timepoint [3] 0 0
28 days
Secondary outcome [1] 0 0
Major Adverse Kidney Events 90: Main Trial Population
Timepoint [1] 0 0
90 Days
Secondary outcome [2] 0 0
Major Adverse Kidney Events 90: Moderate Chronic Kidney Disease Population
Timepoint [2] 0 0
90 Days
Secondary outcome [3] 0 0
Major Adverse Kidney Events 90: COVID-19 Population
Timepoint [3] 0 0
90 Days
Secondary outcome [4] 0 0
Major Adverse Kidney Events Through Day 90: Combined Population
Timepoint [4] 0 0
90 Days
Secondary outcome [5] 0 0
Days Alive and Free of Organ Support Through Day 28: Main Trial Population
Timepoint [5] 0 0
28 days
Secondary outcome [6] 0 0
Days Alive and Free of Organ Support Through Day 28: Moderate Chronic Kidney Disease Population
Timepoint [6] 0 0
28 days
Secondary outcome [7] 0 0
Days Alive and Free of Organ Support Through Day 28: COVID-19 Population
Timepoint [7] 0 0
28 days
Secondary outcome [8] 0 0
Days Alive and Out of the ICU Through Day 28: Main Trial Population
Timepoint [8] 0 0
28 days
Secondary outcome [9] 0 0
Days Alive and Out of the ICU Through Day 28: Moderate Chronic Kidney Disease Population
Timepoint [9] 0 0
28 days
Secondary outcome [10] 0 0
Days Alive and Out of the ICU Through Day 28: COVID-19 Population
Timepoint [10] 0 0
28 days
Secondary outcome [11] 0 0
90-day All Cause Mortality: Main Trial Population
Timepoint [11] 0 0
90 days
Secondary outcome [12] 0 0
90-day All Cause Mortality: Moderate Chronic Kidney Disease Population
Timepoint [12] 0 0
90 days
Secondary outcome [13] 0 0
90-day All Cause Mortality: COVID-19 Population
Timepoint [13] 0 0
90 days

Eligibility
Key inclusion criteria
1. 18 years or older.
2. In the ICU or intermediate care unit for clinical reasons.
3. Have sepsis requiring vasopressor (norepinephrine, epinephrine, dopamine, phenylephrine, vasopressin, or angiotensin II) therapy, i.e.:

1. suspected or proven bacterial or viral infection. and
2. on vasopressor therapy (=0.1 µg/kg/min norepinephrine or equivalent) for sepsis-induced hypotension for at least one hour despite adequate fluid resuscitation according to clinical judgement. Following the initial one hour on at least 0.1 µg/kg/min norepinephrine or equivalent, any dose of vasopressor counts as vasopressor therapy.

The combination of a) and b) automatically ensures that patients fulfill the Sepsis 3 criteria as 0.1 µg/kg/min norepinephrine corresponds to a score of +4 on the Cardiovascular sub-score of the SOFA score.
4. Have AKI according to at least one of the below KDIGO criteria, a to d:

1. An absolute increase in serum or plasma creatinine (CR) by =0.3 mg/dL (=26.5 µmol/L) within 48 hours.

or
2. A relative increase in CR to =1.5 times the pre-AKI reference CR value which is known or presumed to have occurred within prior 7 days.

or
3. A decrease in urinary output to <0.5 mL/kg/hour for a minimum of 6 hours following adequate fluid resuscitation.

or d) If the patient does not have a known history of CKD and there is no pre-AKI reference CR value available from the past 12 months available from the past 12 months: a CR value greater or equal to the levels presented in Table 1, with the increase in CR presumed to have occurred within prior 7 days.
5. Provision of signed and dated ICF in accordance with local regulations.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. a) At sites where enrolment of 'moderate' CKD patients is allowed, patients with 'severe' CKD defined as a pre-AKI reference eGFR <25 mL/min/1.73 m2 are excluded.

* For patients with known CKD, the most recent eGFR prior to index hospitalization needs to be documented as =25 mL/min/1.73 m2.
* For patients with known CKD but no known eGFR prior to hospitalization, presentation eGFR between 25-60 mL/min/1.73 m2 can also be used to rule out 'severe' CKD.

b) At sites where enrolment of 'moderate' CKD patients is NOT allowed, patients with 'moderate' and 'severe' CKD defined as a pre-AKI reference eGFR <45 mL/min/1.73 m2 are excluded.
* For patients with known CKD, the most recent eGFR prior to index hospitalization needs to be documented as =45 mL/min/1.73 m2.
* For patients with known CKD but no known eGFR prior to hospitalization, presentation eGFR between 45-60 mL/min/1.73 m2 can also be used to rule out 'moderate' and 'severe' CKD.
2. Advanced chronic liver disease, defined as a Child-Pugh score of 10 to 15 (Class C).
3. Acute pancreatitis without proven infection.
4. Urosepsis related to suspected or proven urinary tract obstruction.
5. Main cause of AKI not sepsis.
6. Proven or suspected SARS-CoV-2 infection. NOTE: This exclusion criterion does not apply to patients in the COVID-19 population, in which COVID-19 should be the main cause of SA-AKI.
7. Severe burns requiring ICU treatment.
8. Severely immunosuppressed, e.g. due to:

* hematopoietic cell transplantation within past 6 months prior to Screening or acute or chronic graft-versus-host disease
* solid organ transplantation
* leukopenia not related to sepsis, i.e., preceding sepsis
* Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS)
* receiving chemotherapy within 30 days prior to Screening.
9. At high risk of being LTFU, e.g., due to known current or recent (within the last 6 months) IV drug abuse or known to be homeless.
10. Limitations to use of mechanical ventilation (MV), RRT or vasopressors and inotropes (NOTE: limitation of cardiopulmonary resuscitation (CPR) only is not an exclusion criterion).
11. Previous administration of recAP.
12. Use of a non-marketed drug within the last month or concurrent or planned participation in a clinical trial for a non-marketed drug or device. (NOTE: Co-enrollment or concurrent participation in observational, non-interventional trials using no protocolized treatments or procedures are always allowed. Co-enrollment or concurrent participation in trials using protocolized treatments or procedures, e.g. blood draws, requires pre-approval by the TSC).
13. Current or planned extracorporeal membrane oxygenation (ECMO).
14. On RRT >24 hours before start of trial drug.
15. No longer on vasopressor therapy at time of randomization.
16. On continuous vasopressor therapy for >72 hours before start of trial drug.
17. Estimated glomerular filtration rate (eGFR) >60 mL/min/1.73 m2 based on the most recent available CR sample at time of screening (NOTE: will often be the sample used to diagnose AKI). eGFR should be calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula. In Japan, the CKD-EPI formula with Japanese coefficient should be used. If local regulations prohibit correcting for race in the calculation of eGFR, it is acceptable to use the formula without correcting for race.
18. Not feasible to start trial drug within:

1. 48 hours from AKI diagnosis, when AKI diagnosis precedes start of vasopressor therapy.

or
2. 24 hours from AKI diagnosis, when AKI is diagnosed after start of vasopressor therapy.
19. Pregnant or nursing women.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Stopped early
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
2/11/2020
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
18/08/2022
Sample size
Target
Accrual to date
Final
676
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Flinders Medical Centre - Bedford Park
Recruitment hospital [2] 0 0
Bendigo Hospital - Bendigo
Recruitment hospital [3] 0 0
Footscray Hospital - Footscray
Recruitment hospital [4] 0 0
Austin Hospital - Melbourne
Recruitment hospital [5] 0 0
John Hunter Hospital - New Lambton Heights
Recruitment hospital [6] 0 0
Sunshine Hospital ICU - Western Hospital - Saint Albans
Recruitment hospital [7] 0 0
Gold Coast University Hospital (GCUH) - Southport
Recruitment postcode(s) [1] 0 0
5042 - Bedford Park
Recruitment postcode(s) [2] 0 0
3550 - Bendigo
Recruitment postcode(s) [3] 0 0
3011 - Footscray
Recruitment postcode(s) [4] 0 0
3084 - Melbourne
Recruitment postcode(s) [5] 0 0
2305 - New Lambton Heights
Recruitment postcode(s) [6] 0 0
3021 - Saint Albans
Recruitment postcode(s) [7] 0 0
4215 - Southport
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
District of Columbia
Country [4] 0 0
United States of America
State/province [4] 0 0
Georgia
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Kentucky
Country [7] 0 0
United States of America
State/province [7] 0 0
Minnesota
Country [8] 0 0
United States of America
State/province [8] 0 0
New Mexico
Country [9] 0 0
United States of America
State/province [9] 0 0
North Carolina
Country [10] 0 0
United States of America
State/province [10] 0 0
Ohio
Country [11] 0 0
United States of America
State/province [11] 0 0
Pennsylvania
Country [12] 0 0
United States of America
State/province [12] 0 0
Virginia
Country [13] 0 0
United States of America
State/province [13] 0 0
Wisconsin
Country [14] 0 0
Austria
State/province [14] 0 0
Graz
Country [15] 0 0
Austria
State/province [15] 0 0
Innsbruck
Country [16] 0 0
Belgium
State/province [16] 0 0
Brussels
Country [17] 0 0
Belgium
State/province [17] 0 0
Charleroi
Country [18] 0 0
Belgium
State/province [18] 0 0
Genk
Country [19] 0 0
Belgium
State/province [19] 0 0
Gent
Country [20] 0 0
Belgium
State/province [20] 0 0
Jette
Country [21] 0 0
Belgium
State/province [21] 0 0
La Louvière
Country [22] 0 0
Belgium
State/province [22] 0 0
Ottignies
Country [23] 0 0
Belgium
State/province [23] 0 0
Woluwe-Saint-Lambert
Country [24] 0 0
Belgium
State/province [24] 0 0
Yvoir
Country [25] 0 0
Canada
State/province [25] 0 0
Calgary
Country [26] 0 0
Canada
State/province [26] 0 0
Ottawa
Country [27] 0 0
Canada
State/province [27] 0 0
Québec
Country [28] 0 0
Canada
State/province [28] 0 0
Vancouver
Country [29] 0 0
Canada
State/province [29] 0 0
Victoria
Country [30] 0 0
Denmark
State/province [30] 0 0
Aalborg
Country [31] 0 0
Denmark
State/province [31] 0 0
Aarhus N
Country [32] 0 0
Denmark
State/province [32] 0 0
Herning
Country [33] 0 0
Denmark
State/province [33] 0 0
Hillerød
Country [34] 0 0
Denmark
State/province [34] 0 0
København
Country [35] 0 0
Denmark
State/province [35] 0 0
Køge
Country [36] 0 0
Denmark
State/province [36] 0 0
Odense C
Country [37] 0 0
Denmark
State/province [37] 0 0
Randers
Country [38] 0 0
Denmark
State/province [38] 0 0
Slagelse
Country [39] 0 0
Denmark
State/province [39] 0 0
Viborg
Country [40] 0 0
Finland
State/province [40] 0 0
Helsinki
Country [41] 0 0
Finland
State/province [41] 0 0
Tampere
Country [42] 0 0
Finland
State/province [42] 0 0
Turku
Country [43] 0 0
France
State/province [43] 0 0
Angers Cedex
Country [44] 0 0
France
State/province [44] 0 0
Argenteuil Cedex
Country [45] 0 0
France
State/province [45] 0 0
Béthune
Country [46] 0 0
France
State/province [46] 0 0
Cergy-Pontoise
Country [47] 0 0
France
State/province [47] 0 0
Dijon
Country [48] 0 0
France
State/province [48] 0 0
La Roche-sur-Yon
Country [49] 0 0
France
State/province [49] 0 0
Le Kremlin-Bicêtre
Country [50] 0 0
France
State/province [50] 0 0
Le Mans
Country [51] 0 0
France
State/province [51] 0 0
Limoges Cedex
Country [52] 0 0
France
State/province [52] 0 0
Nancy
Country [53] 0 0
France
State/province [53] 0 0
Nantes
Country [54] 0 0
France
State/province [54] 0 0
Nîmes cedex 9
Country [55] 0 0
France
State/province [55] 0 0
Orléans
Country [56] 0 0
France
State/province [56] 0 0
Paris
Country [57] 0 0
France
State/province [57] 0 0
Strasbourg
Country [58] 0 0
France
State/province [58] 0 0
Tours cedex 9
Country [59] 0 0
Germany
State/province [59] 0 0
Aachen
Country [60] 0 0
Germany
State/province [60] 0 0
Hamburg
Country [61] 0 0
Germany
State/province [61] 0 0
Jena
Country [62] 0 0
Germany
State/province [62] 0 0
Leipzig
Country [63] 0 0
Germany
State/province [63] 0 0
Münster
Country [64] 0 0
Ireland
State/province [64] 0 0
G
Country [65] 0 0
Ireland
State/province [65] 0 0
Dublin
Country [66] 0 0
Japan
State/province [66] 0 0
Hachioji-Shi
Country [67] 0 0
Japan
State/province [67] 0 0
Hiroshima-shi
Country [68] 0 0
Japan
State/province [68] 0 0
Izuka-shi
Country [69] 0 0
Japan
State/province [69] 0 0
Izumisano-Shi
Country [70] 0 0
Japan
State/province [70] 0 0
Kashihara-Shi
Country [71] 0 0
Japan
State/province [71] 0 0
Kumamoto-Shi
Country [72] 0 0
Japan
State/province [72] 0 0
Omihachiman-Shi
Country [73] 0 0
Japan
State/province [73] 0 0
Osaka-Shi
Country [74] 0 0
Japan
State/province [74] 0 0
Osaka-shi
Country [75] 0 0
Japan
State/province [75] 0 0
Toyoake-Shi
Country [76] 0 0
Japan
State/province [76] 0 0
Yokohama-Shi
Country [77] 0 0
Netherlands
State/province [77] 0 0
NB
Country [78] 0 0
Netherlands
State/province [78] 0 0
Amsterdam
Country [79] 0 0
Netherlands
State/province [79] 0 0
Ede
Country [80] 0 0
Netherlands
State/province [80] 0 0
Enschede
Country [81] 0 0
Netherlands
State/province [81] 0 0
Heerlen
Country [82] 0 0
Netherlands
State/province [82] 0 0
Nijmegen
Country [83] 0 0
New Zealand
State/province [83] 0 0
WGN
Country [84] 0 0
New Zealand
State/province [84] 0 0
Auckland
Country [85] 0 0
New Zealand
State/province [85] 0 0
Christchurch
Country [86] 0 0
New Zealand
State/province [86] 0 0
Dunedin
Country [87] 0 0
New Zealand
State/province [87] 0 0
Grafton
Country [88] 0 0
New Zealand
State/province [88] 0 0
Hastings
Country [89] 0 0
New Zealand
State/province [89] 0 0
Rotorua
Country [90] 0 0
Spain
State/province [90] 0 0
Badalona
Country [91] 0 0
Spain
State/province [91] 0 0
Barcelona
Country [92] 0 0
Spain
State/province [92] 0 0
Girona
Country [93] 0 0
Spain
State/province [93] 0 0
Madrid
Country [94] 0 0
Spain
State/province [94] 0 0
Sabadell
Country [95] 0 0
Spain
State/province [95] 0 0
Terrassa
Country [96] 0 0
United Kingdom
State/province [96] 0 0
LND
Country [97] 0 0
United Kingdom
State/province [97] 0 0
Cardiff
Country [98] 0 0
United Kingdom
State/province [98] 0 0
Liverpool
Country [99] 0 0
United Kingdom
State/province [99] 0 0
London
Country [100] 0 0
United Kingdom
State/province [100] 0 0
Plymouth

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
AM-Pharma
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Clinical phase 3 study to investigate the effect of recAP on 28 day mortality in patients admitted to the ICU with acute kidney injury that is caused by sepsis.

The study has three distinct SA-AKI trial populations:

1. The main trial population: Patients with a pre-AKI reference eGFR =45 mL/min/1.73 m2 and no proven or suspected SARS-CoV-2 at time of randomization.
2. A 'moderate' CKD population: Patients with a pre-AKI reference eGFR =25 and \<45 mL/min/1.73 m2 and no proven or suspected SARS-CoV-2 at time of randomization.
3. A Corona Virus Disease 2019 (COVID-19) population: Patients with proven or suspected SARS-CoV-2 at time of randomization with or without 'moderate' CKD. For patients in this population, COVID-19 should be the main cause of SA-AKI.

In the main study population approximately 1400 patients will be enrolled and in the two cohorts with moderate CKD and COVID-19 each up to 100 patients.

There are two arms in the study, one with active treatment and one with an inactive compound (placebo). Treatment is by 1 hour intravenous infusion, for three days. Patients are followed up for 28 days to see if there is an improvement on mortality, and followed for 90 and 180 days for mortality and other outcomes e.g. long-term kidney function and quality of life.
Trial website
https://clinicaltrials.gov/study/NCT04411472
Trial related presentations / publications
Pickkers P, Angus DC, Bass K, Bellomo R, van den Berg E, Bernholz J, Bestle MH, Doi K, Doig CJ, Ferrer R, Francois B, Gammelager H, Pedersen UG, Hoste E, Iversen S, Joannidis M, Kellum JA, Liu K, Meersch M, Mehta R, Millington S, Murray PT, Nichol A, Ostermann M, Pettila V, Solling C, Winkel M, Young PJ, Zarbock A; REVIVAL investigators. Phase-3 trial of recombinant human alkaline phosphatase for patients with sepsis-associated acute kidney injury (REVIVAL). Intensive Care Med. 2024 Jan;50(1):68-78. doi: 10.1007/s00134-023-07271-w. Epub 2024 Jan 3. Erratum In: Intensive Care Med. 2024 Apr;50(4):614-615. doi: 10.1007/s00134-024-07357-z.
Pickkers P, Angus DC, Arend J, Bellomo R, van den Berg E, Bernholz J, Bestle M, Broglio K, Carlsen J, Doig CJ, Ferrer R, Joannidis M, Francois B, Doi K, Kellum JA, Laterre PF, Liu K, Mehta RL, Murray PT, Ostermann M, Pettila V, Richards S, Young P, Zarbock A, Kjolbye AL. Study protocol of a randomised, double-blind, placebo-controlled, two-arm parallel-group, multi-centre phase 3 pivotal trial to investigate the efficacy and safety of recombinant human alkaline phosphatase for treatment of patients with sepsis-associated acute kidney injury. BMJ Open. 2023 Apr 3;13(4):e065613. doi: 10.1136/bmjopen-2022-065613.
Public notes

Contacts
Principal investigator
Name 0 0
A Legters
Address 0 0
AM-Pharma
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT04411472